Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data
- PMID: 20043821
- PMCID: PMC2806877
- DOI: 10.1186/1471-2350-10-148
Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data
Abstract
Background: Genetically determined differences in N-acetylation capacity have proved to be important determinants of both the effectiveness of therapeutic response and the development of adverse drug reactions and toxicity during drug treatment. NAT2PRED is a web-server that allows a fast determination of NAT2 acetylation phenotype from genotype data without taking the extra step of reconstructing haplotypes for each individual (publicly available at http://nat2pred.rit.albany.edu). However, the classification accuracy of NAT2PRED needs to be assessed before its application can be advocated at a large scale.
Methods: The ability of NAT2PRED to classify individuals according to their acetylation status (slow, intermediate and rapid acetylators) was evaluated in a worldwide dataset composed of 56 population samples (8,489 individuals) from four continental regions.
Results: NAT2PRED correctly identified slow acetylators with a sensitivity above 99% for all populations outside sub-Saharan Africa. Nevertheless, NAT2PRED showed a poor ability to distinguish between intermediate and rapid acetylators, with a classification error rate reaching up to 10% in the non-African samples.
Conclusion: NAT2PRED is an excellent tool to infer the individual acetylation status from NAT2 genotype data when the main interest is to distinguish slow acetylators from the others. This should facilitate the determination of the individual acetylation status in routine clinical practice and lead to better monitoring of risks associated with cancer and adverse drug reactions.
Figures

Similar articles
-
A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype.Bioinformatics. 2009 May 1;25(9):1185-6. doi: 10.1093/bioinformatics/btp121. Epub 2009 Mar 4. Bioinformatics. 2009. PMID: 19261719 Free PMC article.
-
Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.Ann Hum Genet. 2017 Sep;81(5):190-196. doi: 10.1111/ahg.12198. Epub 2017 Jun 27. Ann Hum Genet. 2017. PMID: 28653770
-
Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.Biomed Res Int. 2020 Jun 15;2020:8765347. doi: 10.1155/2020/8765347. eCollection 2020. Biomed Res Int. 2020. PMID: 32626768 Free PMC article.
-
N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes.Pharmacogenet Genomics. 2020 Apr;30(3):61-65. doi: 10.1097/FPC.0000000000000394. Pharmacogenet Genomics. 2020. PMID: 31895247 Free PMC article.
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
Cited by
-
Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.Clin Infect Dis. 2020 Dec 15;71(12):3136-3143. doi: 10.1093/cid/ciz1212. Clin Infect Dis. 2020. PMID: 31905381 Free PMC article.
-
Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients.Mol Genet Genomic Med. 2021 Oct;9(10):e1764. doi: 10.1002/mgg3.1764. Epub 2021 Sep 12. Mol Genet Genomic Med. 2021. PMID: 34510815 Free PMC article.
-
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.J Antimicrob Chemother. 2022 Aug 25;77(9):2489-2499. doi: 10.1093/jac/dkac188. J Antimicrob Chemother. 2022. PMID: 35678468 Free PMC article.
-
NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.Mol Genet Genomic Med. 2022 Aug;10(8):e1987. doi: 10.1002/mgg3.1987. Epub 2022 Jun 24. Mol Genet Genomic Med. 2022. PMID: 35751408 Free PMC article.
-
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.Am J Respir Crit Care Med. 2024 Jun 15;209(12):1486-1496. doi: 10.1164/rccm.202309-1583OC. Am J Respir Crit Care Med. 2024. PMID: 38647526 Free PMC article.
References
-
- García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649–659. doi: 10.1016/S0140-6736(05)67137-1. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources